[Surfactant replacement therapy: a multicentric trial comparing two dosage approaches]

Area of Science:

• Neonatology
• Pulmonology
• Pharmacology

Context:

• Hyaline Membrane Disease (HMD) is a critical condition in premature infants.
• Exogenous pulmonary surfactant is a standard treatment for HMD.
• Optimal dosing strategies for surfactant therapy require further investigation.

Purpose:

• To compare the efficacy of two initial doses of exogenous porcine surfactant (100 mg/kg vs. 200 mg/kg) in treating very severe HMD.
• To evaluate the impact of initial surfactant dosage on oxygenation and need for retreatment.
• To assess the effect of a modified retreatment protocol on overall surfactant administration.

Summary:

• An interim analysis of a multicenter trial involving 7 Neonatal Units compared 100 mg/kg and 200 mg/kg initial doses of porcine surfactant for very severe HMD.
• The higher initial dose (200 mg/kg) demonstrated improved arterial blood oxygenation and reduced the duration of high oxygen concentration requirements.
• Fewer retreatments were needed in the 200 mg/kg group, and a modified retreatment threshold (FiO2 ≥ 0.40) led to a >40% reduction in total surfactant administered with similar clinical outcomes.

Impact:

• The findings suggest that a higher initial dose of porcine surfactant may be more effective for very severe HMD.
• The study highlights the potential for optimizing surfactant therapy by adjusting retreatment criteria, leading to reduced drug administration.
• This research contributes to evidence-based guidelines for surfactant use in neonatal respiratory distress.